1-6 of 6
Ignacio Matos
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Druggable Targets in Cytokine Release Syndromes

Carlos Luri-Rey, Iñaki Eguren-Santamaria, Ignacio Matos, Pedro Berraondo, Ignacio Melero
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF3.
https://doi.org/10.1158/1078-0432.CCR-23-1975
Published: 21 September 2023
View article titled, Druggable Targets in Cytokine Release Syndromes
Open the PDF for Druggable Targets in Cytokine Release Syndromes in another window
Journal Articles

Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

Maria Lozano-Rabella, Andrea Garcia-Garijo, Jara Palomero, Anna Yuste-Estevanez, Florian Erhard, Roc Farriol-Duran, Juan Martín-Liberal, Maria Ochoa-de-Olza, Ignacio Matos, Jared J. Gartner, Michael Ghosh, Francesc Canals, August Vidal, Josep Maria Piulats, Xavier Matías-Guiu, Irene Brana, Eva Muñoz-Couselo, Elena Garralda, Andreas Schlosser, Alena Gros
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (12): 2250–2265.
https://doi.org/10.1158/1078-0432.CCR-22-3298
Published: 13 June 2023
View article titled, Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
Open the PDF for Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics in another window
Includes: Supplementary data
Journal Articles

Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)

Sarina A. Piha-Paul, Cinta Hierro, Ignacio Matos, Valentina Boni, Noah Hahn, Rhonda Bitting, Todd Bauer, Aggarwal Rahul, Funda Meric-Bernstam, Steven Gourlay, Timothy D. Owens, Ken Brameld, Ann Neale, Richard Schwartz, Steve Murray, Sibel Ucpinar, Peter Foote, Eleni Venetsanakos, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (15_Supplement): A19.
https://doi.org/10.1158/1557-3265.BLADDER19-A19
Published: 03 August 2020
View article titled, Abstract A19: A phase 1, multicenter, dose-escalation study of PRN1371, an irreversible covalent FGFR1-4 kinase inhibitor, in patients with advanced solid tumors including metastatic urothelial carcinoma (mUC)
Journal Articles

Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria

Ignacio Matos, Juan Martin-Liberal, Alonso García-Ruiz, Cinta Hierro, Maria Ochoa de Olza, Cristina Viaplana, Analia Azaro, Maria Vieito, Irene Braña, Gemma Mur, Javier Ros, Jose Mateos, Guillermo Villacampa, Roger Berché, Mafalda Oliveira, Maria Alsina, Elena Elez, Ana Oaknin, Eva Muñoz-Couselo, Joan Carles, Enriqueta Felip, Jordi Rodón, Josep Tabernero, Rodrigo Dienstmann, Raquel Perez-Lopez, Elena Garralda
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (8): 1846–1855.
https://doi.org/10.1158/1078-0432.CCR-19-2226
Published: 15 April 2020
View article titled, Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria
Open the PDF for Capturing Hyperprogressive Disease with Immune-Checkpoint Inhibitors Using RECIST 1.1 Criteria in another window
Includes: Supplementary data
Journal Articles

Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas

Jaume Capdevila, Oriol Arqués, Jose Ramón Hernández Mora, Judit Matito, Ginevra Caratù, Francesco M. Mancuso, Stefania Landolfi, Jorge Barriuso, Paula Jimenez-Fonseca, Carlos Lopez Lopez, Rocio Garcia-Carbonero, Jorge Hernando, Ignacio Matos, Nuciforo Paolo, Javier Hernández-Losa, Manel Esteller, Anna Martínez-Cardús, Josep Tabernero, Ana Vivancos, Héctor G. Palmer
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (4): 902–909.
https://doi.org/10.1158/1078-0432.CCR-19-1266
Published: 14 February 2020
View article titled, Epigenetic <em>EGFR</em> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas
Open the PDF for Epigenetic <em>EGFR</em> Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas in another window
Includes: Supplementary data
Journal Articles

Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?

Cinta Hierro, Ignacio Matos, Juan Martin-Liberal, Maria Ochoa de Olza, Elena Garralda
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (11): 3210–3219.
https://doi.org/10.1158/1078-0432.CCR-18-3694
Published: 03 June 2019
View article titled, Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There?
Open the PDF for Agnostic-Histology Approval of New Drugs in Oncology: Are We Already There? in another window